DZ Bank Call 5.6976 MDG2 19.12.20.../ DE000DQ1YXS8 /
15/11/2024 11:34:59 | Var.0.000 | Denaro15/11/2024 | Lettera- | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
---|---|---|---|---|---|---|---|
0.001EUR | 0.00% | 0.001 Quantità in denaro: 110,000 |
- Quantità in lettera: - |
MEDIGENE AG NA O.N. | 5.6976 EUR | 19/12/2025 | Call |
GlobeNewswire
29/08
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
GlobeNewswire
26/08
Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effecti...
GlobeNewswire
14/08
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08/08
Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell ...
GlobeNewswire
03/07
Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell ...
GlobeNewswire
27/06
Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness
GlobeNewswire
20/06
Medigene AG Announces Lead Selection for MDG2021, Expanding TCR-T KRAS Library Targeting Solid Tumor...
GlobeNewswire
28/05
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology ...
GlobeNewswire
21/05
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...
GlobeNewswire
15/05
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
GlobeNewswire
14/05
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
GlobeNewswire
06/05
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conferenc...
GlobeNewswire
02/05
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell R...
GlobeNewswire
02/05
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein